Skip to main content
Log in

Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Clinical results of tamoxifen (‘Nolvadex’-ICI) monotherapy in 44 premenopausal women with advanced breast cancer have been reviewed. Objective tumor regression was achieved in 12 (27%) patients and a further 10 (22%) were classified as ‘stabilized’. Median duration of response was 12.7 months at the time of analysis. Greatest benefits occurred in soft tissue dominant and receptor-positive tumors, but there was no correlation between tumor response and other clinical manifestations of estrogen deprivation (e.g. menstrual disturbance, hot flushes).

The benefits of conventional doses of tamoxifen do not therefore appear to be influenced by menopausal status and compare favorably to achievements reported after surgical oophorectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Treves N, Finkbeiner JA: An evaluation of therapeutic surgical castration in the treatment of metastatic recurrent and primary inoperable mammary carcinoma in women. Cancer 11: 421–439, 1958

    PubMed  Google Scholar 

  2. Block GE, Lampe I, Vial AB, Coller FA: Therapeutic castration for advanced mammary cancer. Surgery 47: 877–884, 1960

    PubMed  Google Scholar 

  3. Dao TL: Site of metastases and response to therapy in women with cancer of the breast. Acta UICC 18: 928–940, 1962

    Google Scholar 

  4. Taylor SG: Endocrine ablation in disseminated mammary carcinoma. Surg Gynecol Obstet 115: 443–48, 1962

    PubMed  Google Scholar 

  5. Veronesi V, Pizzocaro G, Rossi A: Oophorectomy for advanced carcinoma of the breast. Surg Gynecol Obstet 141: 569–70, 1975

    PubMed  Google Scholar 

  6. Furr BJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE: Tamoxifen.In Goldberg ME (ed): Pharmacological and Biochemical Properties of Drug Substances. APA, Washington, 1979, pp 355–399

    Google Scholar 

  7. Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131–141, 1978

    PubMed  Google Scholar 

  8. Patterson JS, Edwards DG, Battersby LA: A review of the international clinical experience with tamoxifen. Jap J Cancer Clinics Suppl: 157–183, 1981

  9. Manni A, Pearson OH: Antioestrogen induced remissions in premenopausal women with Stage IV breast cancer — effects on ovarian function. Cancer Treat Rep 64: 779–785, 1980

    PubMed  Google Scholar 

  10. Pritchard KI, Thomson BD, Myers RE, Sutherland DJA, Mobbs BG, Meakin JW: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787–796, 1980

    PubMed  Google Scholar 

  11. Margreiter R: Die antioestrogene Substanz Tamoxifen in der Behandlung des fortgeschrittenen Mammakarzinoms. Langenbecks Arch Chir 351: 249–262, 1980

    PubMed  Google Scholar 

  12. Haywood JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens AD: Assessment of response to therapy in advanced breast cancer. Eur J Canc 13: 89–94, 1977

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Margreiter, R., Wiegele, J. Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res Tr 4, 45–48 (1984). https://doi.org/10.1007/BF01806987

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806987

Keywords

Navigation